CLPT ClearPoint Neuro, Inc.

Price Chart

Executive Summary

ClearPoint Neuro held its 2026 annual meeting on May 20, 2026. Stockholders approved the Seventh Amended and Restated 2013 Incentive Compensation Plan, increasing the share reserve by 1,000,000 shares to a total of 7,806,250 shares. All seven director nominees were elected, and the appointment of Cherry Bekaert LLP as auditor was ratified. The board also confirmed committee assignments and R. John Fletcher as Chairman. This is a routine governance filing with no material financial impact.

Actionable Insight

Key Facts

• Stockholders approved the Seventh Amended and Restated 2013 Incentive Compensation Plan, increasing the share reserve by 1,000,000 shares to 7,806,250 shares total.
• All seven director nominees were elected with strong support (over 9.6 million votes 'for' each, with no director receiving more than 204,811 votes 'withheld').
• Ratification of Cherry Bekaert LLP as independent auditor passed with 19,296,330 votes 'for'.
• Advisory vote on executive compensation passed with 8,825,126 votes 'for'.
• Board committee assignments were confirmed: Audit (Fallon chair), Compensation (Johnson chair), Governance (Fletcher chair). R. John Fletcher was confirmed as Chairman of the Board.
• The Plan approval received 7,517,634 votes 'for' and 1,793,261 'against', with 9,991,790 broker non-votes.

Financial Impact

No material financial impact. The incentive plan adds 1,000,000 shares to the reserve, representing approximately 3.8% dilution based on the current share count, but this is a routine replenishment for ongoing equity compensation.

Risk Factors

• Potential future dilution from equity awards under the expanded plan, though this is standard for a growth-stage med-tech company.

Market Snapshot

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

US Market Status